Five Prime Therapeutics Inc
Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer

Abstract:

The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).